Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in
metastatic TNBC leading at the time of disease progression to metastases that are
HR-deficient and sensitive to pembrolizumab and cisplatin therapy. The trial will include in
depth analysis of the patients' TNBC genome and phosphoproteome to evaluate HR-proficiency
and deficiency, and nuclear proteins that drive NHEJ, before and upon progression with
bortezomib therapy.